# Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

> **NCT05373004** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Omar Tarek Elfarargi** · enrollment: 212 (estimated)

## Conditions studied

- Diabetic Nephropathy Type 2

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Enalapril Maleate 20 mg

## Key facts

- **NCT ID:** NCT05373004
- **Lead sponsor:** Omar Tarek Elfarargi
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2024-03
- **Final completion:** 2024-05
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373004, "Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05373004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*